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Epirubicin, cisplatin and continuous infusion of 5-FU is a widely used palliative regimen in patients with gastric cancer. If cisplatin is
substituted by oxaliplatin and 5-FU by capecitabine this regimen can be administered in the outpatient setting. Dose-limiting toxicity
of oxaliplatin is peripheral sensory neuropathy and it is recommended to give oxaliplatin as a 120min infusion. However, in patients
with colorectal cancer a 30min infusion of oxaliplatin can safely be administered without increasing neurotoxicity, standard infusion
time is 30min at our departments. In our phase I study the recommended doses of EXE was established (Dupont et al, 2006).
Patients with non-resectable gastric adenocarcinoma were eligible. Patients received EXE (epirubicin 50mgm
 2 day 1; capecitabine
1000mgm
 2day
 1 continuously and oxaliplatin 130mgm
 2 day 1) as outpatient therapy every third week for a maximum of 8
cycles. From June 2004 to September 2005, we enroled 54 patients. Median age was 60 years (31–74 years) Median number of
courses was 6 (1–8). Response rate was 45%. Median PFS was 6.8 (5.2–7.9) months and median survival was 10.1 (7.9–11.1)
months. Most important grade 3 toxicities were as follows: nausea, vomiting, and diarrhoea (6%). Neurotoxicity grade 2 was seen in
36.5%. We therefore conclude, that EXE every third week is a convenient regimen that easily can be administrated in the outpatient
setting but the regimen needs further evaluation in a phase III study.
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Gastric cancer (GC) remains a significant global health problem
and is one of the most frequent causes of cancer-related deaths.
Although the incidence has been declining in Europe during the
last century it is still the fifth most common cancer and an
estimated 171000 new cases of GC will be diagnosed each year
(Boyle and Ferlay, 2005). The prognosis is very poor, with a 5-year
overall survival of approximately 10% in Denmark (Coleman et al,
2003). The only potentially curative treatment for GC is surgery,
but unfortunately most cases are diagnosed at an advanced stage
because of very few organ-specific symptoms and therefore only
about 20% of the patients are suitable for curative surgery
(Janunger et al, 2001).
Therefore the need for palliative treatment is huge for these
patients. The efficiency of palliative chemotherapy is widely
accepted. Data from randomised studies have shown that combina-
tion chemotherapy results in a significant survival advantage and
improves quality of life in patients with advanced GC (Murad et al,
1993; Pyrhonen et al, 1995; Glimelius et al, 1997; Wagner et al, 2006).
In the past decade a number of effective chemotherapy regimens
have been established worldwide. However, these studies have not
resulted in a standard regimen for gastric cancer, but the backbone
of these regimens is most often a combination of 5-fluorouracil
(5-FU) and platinum. In Europe ECF (epirubicin 50mgm
 2 day 1,
cisplatin 60mgm
 2 day 1 and continuous infusion (CVI) of 5-FU
200mgm
 2 daily) is widely used as it was shown that ECF
improves response rate and prolongs survival when compared with
FAMtx which was considered to be a standard therapy a decade
ago (Webb et al, 1997; Waters et al, 1999).
We sought to find a regimen that was comparable with ECF in
efficacy, easy to administer in an outpatient setting and with low
toxicity.
Therapy with 5-FU requires a central venous catheter which is
associated with risk of venous thromboses and infection (Findlay
et al, 1994; Evans et al, 1996). Capecitabine is an oral
fluoropyrimidine, which is absorbed from the gastrointestinal
tract as an intact molecule and afterwards converted into 5-FU in a
cascade of three enzymatic steps (Miwa et al, 1998). Capecitabine
is a well-established alternative which simplifies the administration
of 5-FU and overcomes the problem with the central venous
catheter.
Another cornerstone in ECF is cisplatin, which is highly emetic
and in addition intravenous hydration is required to prevent renal
toxicity.
Oxaliplatin is a third-generation platinum that easily can be
administered in outpatients without hydration. When compared
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swith cisplatin, oxaliplatin has a better safety profile with regard to
renal toxicity and emesis. Recent studies have shown synergism
between oxaliplatin and 5-FU and a combination of these two
drugs has proven effective as first- or second-line treatment for
advanced colorectal cancer (De Gramont et al, 2000; Raymond
et al, 2001; Cassidy et al, 2004). The dose-limiting toxicity of
oxaliplatin is peripheral sensory neuropathy, which is reversible
but cumulative. Usually it is recommended to give oxaliplatin as a
120min infusion to minimize peripheral neuropathy. However, we
have recently in patients with colorectal cancer demonstrated that
a 30min infusion apparently does not result in more neurotoxicity
(Pfeiffer et al, 2003, 2006).
We therefore used 30min infusion of oxaliplatin in both our
phase I and phase II trial (Dupont et al, 2006). The primary aims of
our phase II study were to evaluate response rate and toxicity of
EXE in patients with advanced gastric cancer. Secondary end
points were progression-free survival and overall survival.
MATERIALS AND METHODS
Patient selection
Eligible patients were required to have histological verified non-
resectable gastric or gastro-oesophageal junction adenocarcinoma
and at least one measurable lesion according to RECIST criteria.
Eligibility criterias also included WHO performance status 0–2;
age between 18 and 75 years; estimated life expectancy of at least 3
months; adequate hepatic function (serum bilirubin o1.5 upper
normal limit (UNL); transaminase o3 UNL, however in cases of
livermetastases, there was no upper limit for transaminases);
adequate renal function (calculated creatinine clearance
430mlmin
 1 by the Cockroft and Gault formula); adequate
haematological function (neutrophil count 41.5 10
9l
 1; platelets
4100 10
9l
 1 and no prior chemotherapy other than adjuvant
chemotherapy, completed at least six months before inclusion.
Other inclusion criterias were ability to tolerate and comply with
oral medication, no sign of peripheral neuropathy, no co-existent
severe medical illness, no sign of brain metastases and no
concomitant treatment with other anticancer therapy. Females
were not included if they were pregnant or lactating.
The study was approved by the local ethics committee and
Danish health authority and all participants gave written informed
consent before entering the study.
Study design and treatment
Patients were planned to receive a combination of epirubicin
50mgm
 2 as a 20min. i.v. infusion day 1, oxaliplatin 130mgm
 2
as a 30min. i.v. infusion day 1 and capecitabine 500mgm
 2 2
daily continuously each 3 weeks (Dupont et al, 2006).
Therapy was repeated every 3 weeks up to a maximum of eight
cycles of treatment unless stopped before because of disease
progression, unacceptable toxicity or patient refusal.
Reduction of 25% in all drug doses was recommended in the
event of occurrence of febrile neutropenia, grade 4 thrombocyto-
penia (platelet count o25 10
9l
 1) or grade 4 neutropenia
(absolute neutrophil count o0.5 10
9l
 1), grade 3–4 mucositis,
diarrhoea, or nausea/vomiting in spite of optimal antiemetic
treatment. Toxicity was graded according to NCIC-CTC version
2.0. Peripheral sensitive neuropathy to oxaliplatin was graded
according to the following oxaliplatin-specific scale. Grade 1,
parestesias/hypoesthesias of short duration with complete recov-
ery before the next cycle; grade 2, parestesias/hypoesthesias
persisting between two cycles without functional impairment;
and grade 3 permanent parestesias/hypoesthesias resulting in
functional impairment (Caussanel et al, 1990). In case of grade 2
neuropathy oxaliplatin was reduced 25%.
Patient evaluation
Baseline evaluation included physical examination, assessment of
medical history, evaluation of performance status and blood
counts. During treatment patients were evaluated before each cycle
of therapy with the above parameters. All patients had an
abdominal and thoracic CT-scan performed at baseline and every
third cycle to assess tumour response. Tumour response was
classified according to RECIST guidelines and confirmed as lasting
longer than 4 weeks.
After the end of the therapy patients were followed every third
month until progression or death.
Statisistical methods
The primary end point of this phase II study was response rate to
EXE and secondary end points were progression-free survival
(PFS), and overall survival (OS). Progression-free survival was
defined as the time from inclusion to progressive disease occurred
(according to the RECIST criteria) or death of any cause. Overall
survival was defined as the time from inclusion to death of any
cause. Progression-free survival and OS were updated until
1 September 2007.
Non-parametric statistics was applied. All median values are
followed by range in brackets. After cessation of treatment patients
without documented progression were followed every 3 months
with clinical and radiological evaluation. Progression-free survival
and OS were generated according to the Kaplan–Meier method.
Data were recorded and analysed in a Medlog
s database. All
analyses were done on an intention-to-treat population.
RESULTS
Patient charasteristics
Between June 2004 and August 2005, 54 patients with gastric and
gastro-oesophageal adenocarcinoma were treated at three Danish
oncology centres. Baseline patient characteristics are shown in
Table 1. The median age was 59 years (range, 31–74 years).
Performance status was 0 in 25 patients, one in 26 patients and two
in three patients. No patients had previously received adjuvant
chemotherapy or radiotherapy. Forty-three patients had adeno-
carcinoma located in cardia and 11 patients had adenocarcinoma
located in the corpus or antrum of the stomach. Nine patients
(17%) had locally advanced disease and 45 patients (83%) had
metastatic disease. Twenty-four patients had more than one organ
involved (range, 2–4).
Toxicity
Fifty-three patients were evaluable for toxicity as one died of
gastrointestinal bleeding 5 days after the first cycle of chemother-
apy. Worst toxicity for all patients and all cycles are listed in
Table 2. Neutropenia was the principal haematologic toxicity, 13%
of the patients experienced grade 2 neutropenia, 15% grade 3 and
2% grade 4 neutropenia, but no patient had febrile neutropenia.
Infection grade 2–3 without neutropenia was seen in 12%. In
general grade 4 toxicity was rare, one patient experienced grade 4
neutropenia and one had vomiting in grade 4.
Non-haematologic toxicities were primary grade 2 toxicity,
diarrhoea (13%), nausea (32%), vomiting (22%), hand food
syndrome (PPE) (10%) and peripheral neuropathy (36%). No
patients had peripheral neuropathy or PPE grade 3 or 4, and only
6, 4, and 6% had diarrhoea, vomiting or nausea grade 3,
respectively. Except for the patient who died of gastrointestinal
bleeding there was no treatment-related death in this study.
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The median number of EXE was 6 (range, 1–8), 19 patients
completed eight cycles of treatment. The reasons for discontinua-
tion of EXE were progressive disease or deterioration of health
(n¼21), toxicity (n¼7), patient refusal (n¼5) and other (n¼2).
One patient had complete response and 23 obtained partial
response, giving an overall response rate of 45% in the ITT
population.
Progression-free survival was 6.8 months (range, 5.2–7.9) and
median survival was 10.1 months (range, 7.9–11.1) (Figure 1). Five
patients are still alive 24–37 months after inclusion, one without
active disease and four patients who have either had surgery or
second- and third-line chemotherapy after progression.
DISCUSSION
Combination chemotherapy prolongs survival and improves
quality of life in patients with advanced GC but still they have a
poor prognosis and no standard regimen has yet been established.
In many areas of Europe, ECF has been regarded as a reference
regimen in patients with advanced gastric or gastrooesophageal
cancer as randomized studies have confirmed a high response rate
around 45% and long overall survival around 9–10 months (Webb
et al, 1997; Ross et al, 2002).
The introduction of the new anticancer drugs oxaliplatin and
capecitabine made it possible to overcome problems with
hydration and central venous catheter. A large randomized phase
lll study, REAL-2, used ECF as control and substituted cisplatin
with oxaliplatin and CVI 5-FU with capecitabine in a 2 2 factorial
design. An impressive 1002 patients were enroled in REAL-2.
Response rates were highest in the EOX group (47.9%) but did not
differ significantly between the four groups. There was a
nonsignificant difference in PFS among the groups, but there
was a trend towards prolonged OS in patients receiving oxaliplatin
and capecitabine EOX (Cunningham et al, 2008). In another phase
III study, 220 patients were randomised to receive 24-h infusion
5-FU, leukovorin and cisplatin or 24-h infusion 5-FU, leukovorin
and oxaliplatin (FLO). The authors also observed a trend towards a
longer TTP in the FLO arm (median 5, 7 vs 3.8 months) (Al-Batran
et al, 2006). Recently, a phase II study with 36 patients also
evaluated a therapy with epirubicin, oxaliplatin and 5-FU. The
response rate was 46%, PFS was 8.2 months and OS 12.2 months
(Neri et al, 2007) Toxicity profile was very similar to the data in
this study.
In recent years, ongoing or completed studies are evaluating
new drugs or combinations of drugs in locally advanced or
metastatic gastric cancer. Docetaxel, one of the ‘new’ drugs, was
Table 2 Worst toxicity after median 6 cycles of EXE
Grade 2
n (%)
Grade 3
n (%)
Grade 4/5
n (%)
Haematologic toxicity
Neutropenia 7 (13) 8 (15) 1 (2)
Thrombocytopenia 1 (2) 1 (2) 0
Infection (no neutropenia) 3 (6) 3 (6) 0
Febrile neutropenia 0 0 0
Nonhaematologic toxicity
Diarrhoea 7 (13) 3 (6) 0
PPE 5 (10) 0 0
Nausea 17 (32) 3 (6) 0
Vomiting 12 (22) 2 (4) 1 (2)
Neuropathy 19 (36) 0 0
Bleeding 1 (2)
0
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Figure 1 Time-to-progression and overall survival. Kaplan–Meier curves
of time-to-progression (median 6.8 months; 95% CI 5.2–7.9 months) and
overall survival (median 10.1 months; 95% CI 7.9–11.1 months).
Table 1 Patient characteristics at baseline
Characteristic N
Age
Median 59
Range 31–74
WHO performance status
02 5
12 6
23
Location
Cardia 43
Corpus 11
Prior adjuvant chemotherapy 0
No. of organs involved
13 0
21 7
437
Stage
Locally advanced disease 9
Metastatic disease 45
Status of primary tumour
R0 resection 9
R1 resection 2
R2 resection 4
No surgery 39
Increased alkaline phosphatase (4300Ul
 1)4
Increased ALAT (0Ul
 1)8
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patients receiving docetaxal, cisplatin and 5-FU (DCF) or cisplatin
and 5-FU (CF). TTP (5.6 vs 3.7 months) and OS (9.2 vs 8.6 months)
were significantly longer for patients receiving DCF (Van Custem
et al, 2006). Docetaxel has also been used in combination with
capecitabine, irinotecan and epirubicin in different phase II
studies. An ongoing phase I and II study in five Danish oncology
centres evaluates a combination of docetaxel, epirubicin and
capecitabine. The primary end point for phase I is dose-limited
toxicity. Primary end point for phase II study is response rate and
secondary end points are PFS and OS.
The aims of the present phase II study, was to confirm the
efficacy, convenience and tolerability of short-time EXE. We found
a promising response rate of 46%, PFS of 6.8 months and OS of
10.1 months and all these efficacy data are comparable to the data
observed in similar studies.
Short-time EXE is very well tolerated. Only seven patients (13%)
stopped chemotherapy because of toxicity. Worst haematologic toxicity
was neutropenia (grade 3–4 toxicity in 17 patients) but no patient had
febrile neutropenia. Non-haematologic toxicity was primarily diar-
rhoea, nausea and vomiting but only two patients experienced nausea/
vomiting grade 3–4. Despite the fact that oxaliplatin was infused in
30min no patient developed peripheral neuropathy grade 3 and no
patient experienced laryngopharyngeal dysaesthesia.
We therefore conclude, that a combination of epirubicin,
capecitabine and oxaliplatin every third week is a convenient
regimen that easily can be administrated in the outpatient setting
but the regimen needs further evaluation in a phase III study.
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